Why ProKidney Corp.’s (PROK) Stock Is Down 5.15%
As of Friday, October 16, ProKidney Corp.’s PROK share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Commentary & Analysis
Why ProKidney Corp.’s (PROK) Stock Is Up 5.56%
As of Friday, September 18, ProKidney Corp.’s PROK share price has surged by 5.56%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why ProKidney Corp.’s (PROK) Stock Is Up 6.03%
As of Wednesday, September 16, ProKidney Corp.’s PROK share price has surged by 6.03%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why ProKidney Corp.’s (PROK) Stock Is Down 5.78%
As of Wednesday, September 09, ProKidney Corp.’s PROK share price has dipped by 5.78%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why ProKidney Corp.’s (PROK) Stock Is Up 6.77%
As of Friday, September 04, ProKidney Corp.’s PROK share price has surged by 6.77%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | PROK | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $276.8 | $208.8 | 32% |
|
| Shares Out (Mil) | 186.6 | 53.9 | 74% |
|
| Institutional Ownership | 96.8% | 93.1% | 71% |
|
| Float (Mil) | 184.6 | 41.4 | 72% |
|
| Beta | 1.75 | 0.95 | 88% |
|
| Avg Daily Volume (000s) | 1,218 | 614 | 73% |
|
| Price Change (52-week) |
(58.2%) | 45.3% | 17% |
|
| Growth | PROK | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (20.9%) | (10.2%) | 19% |
|
| EPS (5yr) | (15.1%) | 15.7% | 18 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 22.0% | (15.7%) | 81% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.140) | ($0.562) | ($0.586) | |
| Month Ago EPS | ($0.140) | ($0.562) | ($0.586) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.141) | ($0.538) | ($0.576) | |
| Year/Year Chg | (7.9%) | 9.1% | (25.4%) | |
| Financials | PROK | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 2% |
|
| Net Income (TTM) (Mil) | ($84) | ($44) | 12% |
|
| EPS (TTM) | ($0.557) | ($1.600) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($141) | ($33) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($10) | $2 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 21% |
|
| Enterprise Value (Q1) (Mil) | $1,299 | $174 | 44% |
|
| Valuation | PROK | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.09 | na |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PROK | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.0% | 96% |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (27.1%) | (47.2%) | 18% |
|
| ROE | 8.9% | (54.2%) | 54% |
|
| Liabilities to Assets | 10.5% | 29.1% | 6% |
|
| F-Score | 2 | 2 | 7% |
|
ProKidney Corp. did not pass any screens on 10/16/2026.
